Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research.

TRUSOLINO, Livio;
2014-01-01

Abstract

Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.
2014
4
9
998
1013
http://cancerdiscovery.aacrjournals.org/content/4/9/998.long
tumor xenografts; Drug Development; therapeutic response; personalized medicine
Hidalgo M;Amant F;Biankin AV;Budinská E;Byrne AT;Caldas C;Clarke RB;de Jong S;Jonkers J;Mælandsmo GM;Roman-Roman S;Seoane J;Trusolino L;Villanueva A
File in questo prodotto:
File Dimensione Formato  
2014_Patient-Derived Xenograft Models An Emerging Platform for Translational Cancer Research.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 6.56 MB
Formato Adobe PDF
6.56 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Cancer Discovery 2014.pdf

Open Access dal 16/09/2015

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 927.95 kB
Formato Adobe PDF
927.95 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/150495
Citazioni
  • ???jsp.display-item.citation.pmc??? 616
  • Scopus 1222
  • ???jsp.display-item.citation.isi??? 1152
social impact